LAFAYETTE, N.Y. — Ichor Life Sciences, based in LaFayette, has completed its acquisition of Woodland Biosciences, Inc. of Massachusetts.
The in-vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division, per a company news release.
The companies didn’t disclose any financial terms of this acquisition agreement.
(Sponsored)
Cybersecurity in Today’s Remote Work Environment
The response to the COVID-19 pandemic demonstrated that remote work was viable for many companies. Today, remote and hybrid work models have become standard options for most professionals. While remote
In the Market to Build? Get Started in 4 Simple Steps
Finding the perfect home isn’t always easy, especially in our world today. The U.S. Housing Shortage has created an ongoing challenge for homebuyers across the nation, opening the door to
Ichor Life Sciences describes itself as a preclinical contract-research organization offering services in discovery through pharmacology.
Ichor describes Woodland Biosciences as a preclinical contract-research organization. It was previously located on the campus of Tufts Veterinary Medicine School in North Grafton, Massachusetts.
Woodland’s research and development (R&D) facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette. Michael Briggs, the president of Woodland Biosciences, is now part of Ichor’s scientific leadership in pharmacology.
Briggs has “deep expertise and experience” in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others, Ichor said.
“Woodland Biosciences’ capabilities in developing orthotopic and syngeneic models with a focus on liver and pancreatic cancers, along with models in NASH and other metabolic diseases, expands the specialization within our Ichor Pharmacology group,” Kelsey Moody, CEO of Ichor Life Sciences, said. “As we seek to continuously add to our portfolio of services and broaden our expertise, we plan to identify other opportunities for acquisitions in the months ahead.”
